Treatment Satisfaction With Ra-223 in Japan

CompletedOBSERVATIONAL

Enrollment

Participants

Timeline

Start Date

April 11, 2019

Primary Completion Date

December 1, 2022

Study Completion Date

March 20, 2023

Conditions

Prostatic Neoplasms

Interventions

DRUG

Radium-223 dichloride (Xofigo, BAY88-8223)

Ra-223 is a radiopharmaceutical with an indication to treat Castration Resistant Prostate Cancer (approved indication in Japan)

Trial Locations (1)

Many Locations, Multiple Locations